BRIEF published on 05/20/2025 at 18:50, 1 year 3 months ago Arkema émet une obligation hybride à durée indéterminée de 400 millions d'euros ARKEMA Obligation Hybride Science Des Matériaux Matériaux Spéciaux Financement Diversifié
BRIEF published on 05/20/2025 at 18:50, 1 year 3 months ago Arkema Issues €400 Million Undated Hybrid Bond ARKEMA Specialty Materials Hybrid Bond Materials Science Diversified Financing
PRESS RELEASE published on 05/20/2025 at 18:45, 1 year 3 months ago Informations privilégiées / Autres communiqués Arkema a placé avec succès 400 millions d’euros d’obligations hybrides à durée indéterminée. Le financement diversifie ses sources et contribue au refinancement de ses obligations existantes Financement Refinancement Matériaux Durables ARKEMA Obligations Hybrides
PRESS RELEASE published on 05/20/2025 at 18:45, 1 year 3 months ago Inside Information / Other news releases Arkema issues €400 million undated hybrid bond with 4.25% annual coupon, aimed at refinancing an outstanding bond and diversifying financing resources Financing Refinancing ARKEMA Hybrid Bond Materials Science
BRIEF published on 05/20/2025 at 11:44, 1 year 3 months ago Arkema annonce des opérations de rachat d'actions Rachat D'actions Transactions Boursières ARKEMA Conformité À La Réglementation Marché De L'UE
BRIEF published on 05/20/2025 at 11:44, 1 year 3 months ago Arkema Announces Share Buyback Transactions Share Buyback Stock Transactions Regulation Compliance EU Market ARKEMA
PRESS RELEASE published on 05/20/2025 at 11:39, 1 year 3 months ago Informations privilégiées / Autres communiqués Arkema annonce les transactions sur actions propres effectuées du 12 au 16 mai 2025, conformément à la réglementation en vigueur Actions Propres Transactions Réglementation Achats ARKEMA
PRESS RELEASE published on 05/20/2025 at 11:39, 1 year 3 months ago Inside Information / Other news releases Arkema discloses trading in own shares from 12 to 16 May 2025 in compliance with regulations. Total volume of 15,000 shares acquired at weighted average price of 68.9536 Share Buyback Trading Compliance ARKEMA Weighted Average Price
BRIEF published on 05/19/2025 at 08:35, 1 year 3 months ago Arkema Strengthens Its Offer of Eco-Friendly Refrigerants Environment Refrigerants ARKEMA HFO HVAC-R
BRIEF published on 05/19/2025 at 08:35, 1 year 3 months ago Arkema Renforce Son Offre de Réfrigérants Écologiques Environnement Refrigerants ARKEMA HFO CVC-R
Published on 09/11/2026 at 04:00, 7 hours 50 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 25 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 20 hours 30 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 50 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 11:43, 7 minutes ago Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 15 minutes ago EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 20 minutes ago Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 1 hour 35 minutes ago TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 07:00, 4 hours 50 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 50 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 50 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 16 hours 20 minutes ago Availability of the 2026 Interim Financial Report
